Mayo Clinic Ventures

Type

Private equity

Status

Active

Location

Rochester, United States

Total investments

38

Average round size

18M

Portfolio companies

27

Rounds per year

1.00

Lead investments

5

Follow on index

0.29

Exits

3

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareArtificial IntelligenceHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

The company was established in North America in United States. The main department of described VC is located in the Rochester.

The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Mayo Clinic Ventures works on 8 percentage points less the average amount of lead investments. Considering the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. The high activity for fund was in 2019.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Mayo Clinic Ventures, startups are often financed by Sanderling Ventures, Thomas, McNerney & Partners, i2E. The meaningful sponsors for the fund in investment in the same round are Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures. In the next rounds fund is usually obtained by Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures.

We also calculated 1 valuable employee in our database.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Torax Medical, Qlaris Bio, Cadence Neuroscience The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biotechnology. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

Show more

Investor highlights

Check size
Up to 20M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
38
Lead investments
5
Exits
3
Rounds per year
1.00
Follow on index
0.29
Investments by industry
  • Health Care (32)
  • Biotechnology (27)
  • Medical (12)
  • Therapeutics (10)
  • Medical Device (9)
  • Show 31 more
Investments by region
  • United States (34)
  • China (1)
  • Israel (1)
  • Ireland (2)
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
5M
Group Appearance index
0.87
Avg. company exit year
15

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
JOGO Health 30 Aug 2021 Biotechnology, Fitness, Health Care, Pharmaceutical Seed 4M United States, New Jersey, Bridgewater
Qlaris Bio 30 Apr 2024 Biotechnology, Health Care, Medical Early Stage Venture 24M United States, Massachusetts, Cambridge
YoQueVos 01 Sep 2011 Beauty, Fashion, Women's Seed 25K Argentina, Entre Ríos Province

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.